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doi:10.1016/j.ejvs.2009.11.004Abstract Screening for abdominal aortic aneurysm (AAA) in high-risk groups has been recom-
mended based on a high prevalence of disease, while being questioned due to a high frequency
of co-morbidities and inferior life-expectancy. We evaluated the long-term outcome and the
cost-effectiveness of selective AAA screening among patients referred to the vascular labo-
ratory for arterial examination.
Methods: A total of 5924 patients, referred to the vascular laboratory of a university hospital,
were screened for AAA with ultrasound (definition: B 30 mm), 1993e2005. Outcome data
were gathered through hospital records and the national population registry. A Markov model
was used for healtheeconomic evaluation.
Results: An AAA was detected in 181 patients (mean age 72.8 years), of whom 21.5% under-
went elective repair (perioperative mortality 5.1%) after 7.5 years of follow-up. Four of six
patients diagnosed with AAA rupture were operated upon. Relative 5-year survival compared
with the general Swedish population, controlled for age and sex, was 80.4% (95% confidence
interval (CI): 70.8e88.8). The cost-effectiveness was robust in base-case (11 084 Euro/life year
gained) and in sensitivity analyses of prevalence, cost and survival.
Conclusions: Patients in whom AAA was detected at selective screening had inferior long-term
survival and were operated on less frequently, compared with AAA patients described in
previous studies. Yet, selective screening at the vascular laboratory was cost-effective.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.i.uu.se (K. Mani).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Selective Screening for AAA 209To decrease the number of deaths from ruptured abdominal
aortic aneurysm (AAA), early detection by screening
persons at high risk for AAA is advocated, and randomised
controlled trials have shown that screening men aged
65e80 years reduces AAA-related mortality by about 50% in
a cost-effective manner.1e5 Currently, population-based
screening is being implemented in several countries.6e8
A more selective approach, with screening of specific
high-risk groups has been suggested,9e12 and is imple-
mented within the Medicare programme in the United
States.13 A history of smoking and known atherosclerotic
disease are some of the criteria that have been suggested
for selective AAA screening based on a high expected
prevalence of disease.11,14e16 However, high-risk screening
has also been questioned due to an expected high
frequency of co-morbidities in these patient groups,
affecting operability and long-term survival negatively,17,18
reducing the cost-effectiveness of this screening strategy.
Despite these concerns, selective screening for AAA
among patients undergoing arterial examinations due to
suspected cardiovascular disease has been reported from
several centres.19e22 The aim of this study was to investi-
gate the long-term outcome and the cost-effectiveness of
selective high-risk screening for AAA among patients
referred to the vascular laboratory for arterial duplex scan.Methods
Since 1993, patients referred to the vascular laboratory at
the Uppsala University Hospital for peripheral arterial
duplex examination are screened for AAA.22 Among 5924
selectively screened patients between 1993 and 2005, 181
were found to have an AAA, and they form the basis of this
study (in addition to the 179 AAAs detected at screening
previously reported from this cohort,22 two AAAs were
identified during the completion of the current study).
Patient records were reviewed retrospectively for all
patients with AAA detected at screening. Patient co-
morbidities at the time of screening were registered.
Follow-up examinations related to the detected AAA were
recorded, as well as AAA-related interventions and their
outcome. Survival data were obtained through cross-
checking with the Swedish national population registry. For
deceased patients, the cause of death according to the
death certificate was retrieved from the Swedish cause of
death registry. Relative survival23 was calculated by
comparing the observed survival of patients with AAA
detected at selective screening to the expected survival of
the entire Swedish population adjusted for gender, age and
calendar year. The expected survival and the standardised
mortality ratio (SMR) were calculated by using life tables
obtained from the Human Mortality Database.24
The cost-effectiveness of a selective high-risk screening
programme in this setting (compared with non-screening)
was assessed using a previously described17 Markov cohort
simulation model (Fig. 1). The cost (Euro, 2006 value) per
life year gained (LYG) was the main outcome measure and
cost per quality-adjusted life years (QALY) a secondary
outcome measure. An incremental cost per effect of
< 50 000 Euro was regarded as acceptable.25 Model proba-
bilities were based on follow-up data from the presentcohort when obtainable, or from a literature review on
outcome of AAA17 (Table 1). Cost of selective AAA screening
at the vascular laboratory was estimated based on addi-
tional time required for aortic examination during
a peripheral arterial examination (average 4 min). Follow-
up cost for AAA patients not requiring surgery was calcu-
lated based on AAA-related follow-up visits and cost per
visit.26 In patients where AAA surgery was performed, cost
was estimated based on average cost of AAA repair and
follow-up after aortic surgery studied previously at our
institution.26 Model parameters were varied, based on
literature review and results of current study, in one-way
sensitivity analyses to evaluate the effect of uncertainties
on the cost-effectiveness of the screening strategy.
Data from the general Swedish population was used to
estimate the QALYs gained through AAA screening within
the Markov model (based on EQ-5D,27 utility index 0.79 for
70e79-year-olds and 0.74 for > 80-year-olds). As a base-
case, it was assumed that the screening population has the
same utility index as the age-matched general population.
To evaluate the effect of reduced utility index on healthe
economic outcome of screening, two purely hypothetical
scenarios were tested: (1) the entire screening population
has a 25% reduction in utility (due to general co-morbid-
ities) and (2) patients with a known AAA suffer a 10%
reduction in utility until the aneurysm is repaired (due to an
assumed negative psychological effect of a known AAA on
the patient), and the rest of the population has the same
utility as an age-matched general population.
Data evaluation was carried out with software packages
(statistical analysis: SPSS PC version 16.0, SPSS, Chicago, IL,
USA; healtheeconomic evaluation: TreeAge Pro 2007,
TreeAge Software, Inc., Williamstown, MA, USA). Indepen-
dent samples t-test was used for comparison of normally
distributed continuous variables and Fisher’s exact test was
used to compare proportions of nominal variables. The
study was approved by the Committee of Ethics of Uppsala
University.
Results
Long-term outcome
After a mean follow-up of 7.5 years (standard deviation
(SD) 2.8) 47.5% of the patients were alive. Patients’ char-
acteristics are described in Table 2. In general, 106 patients
underwent surveillance. In 19 patients surveillance was
initiated, but later terminated, due to poor general health
(14 patients) or due to no expansion of the AAA (5 patients).
In 75 patients no surveillance was initiated. In 11 of these,
poor general health was explicitly mentioned as the cause
for not following up on the patient further. In the remaining
64 patients, no specific cause was recorded in the patient
charts. Fifty-nine of these patients had aneurysms  40 mm
in diameter, and 39 were  75 years of age.
Mean resources used per patient during follow-up
amounted to an estimated total cost of 1579 Euro. Mean
survival was 8.3 years (95% confidence interval (CI): 7.4e9.3)
and 5-year survival was 63.3% (95%CI: 56.0e70.6). Relative 5-
year survival for the entire patient group, compared with the
general Swedish population matched for age, sex and
Figure 1 Markov model structure.
210 K. Mani et al.calendar year, was 80.4% (95% CI: 70.8e88.8). The SMR was
2.0 (95% CI 1.5e2.5). Cardiovascular disease was the major
cause of death in this patient group, Table 3.
Thirty-nine patients (21.5%) underwent elective AAA
repair (Table 2). A total of 60% of the patients reaching an
AAA diameter of >50 mm during follow-up underwent
elective repair. Mean time from screening to elective AAA
repair was 2.8 years (SD 2.6). Nine patients underwent
elective repair within 6 months from screening. Among men
with a duplex-verified arterial stenosis, the AAA prevalence
was 6.5% (78/1197), of which 28.2% (nZ 22/78) underwent
elective repair. The corresponding figures for men without
stenosis was 2.9% (58/1976) and 12.1% (nZ 7/58), for
women with stenosis 2.7% (26/972) and 19.2% (nZ 5/26)
and for women without stenosis 0.8% (13/1602) and 15.4%
(nZ 2/13).
Twenty-seven patients underwent open, 11 endovas-
cular and one a hybrid repair. There were two perioperative
deaths (5.1%). One patient died after repair of a thoraco-
abdominal aneurysm with a hybrid procedure with devia-
tion of the visceral arteries and stent-grafting of the aorta.
Another patient died in the perioperative period after open
repair of a pararenal aneurysm. Perioperative surgical
complications included two cases of bowel ischaemia, two
cases of extremity ischaemia, one re-operation for bleeding
and one wound rupture. Long-term complications requiring
open surgical re-intervention consisted of one aortoe
duodenal fistula, two pseudo-aneurysms and one endoleak
with expansion of the AAA. One case of endotension with
expansion and one case of graft thrombosis were treated
endovascularly.
A total of six registered ruptures occurred in the cohort,
which equals a 0.6% rupture risk per year. Four patients
were operated on for a ruptured AAA, all with open repair.Two ruptured during surveillance (B at last follow-up:
50 mm in both cases); both survived the operation.
However, both developed late graft infection with fatal
outcome; one died due to aorto-enteric fistula 1 year
postoperatively and one due to septic complications 2 years
postoperatively. One patient had terminated surveillance
prior to rupture due to poor general health (B at last
follow-up: 69 mm), and died despite attempted surgical
repair. One patient had not been followed up (B at AAA
detection: 42 mm), survived repair for a ruptured AAA and
died 15 months later from cardiac disease. Two additional
patients who had not undergone any AAA repair were
registered as ruptures in the cause of death registry. One of
these patients had been followed up for an expanding
aneurysm but was eventually regarded as too high risk for
elective repair (B at last follow-up: 53 mm). The other
patient, a 78-year-old male with a 35 mm AAA at detection,
was not included in surveillance.Healtheeconomic evaluation
The incremental cost-effectiveness ratio (ICER) of
a screening programme compared with non-screening was
11 084 Euro/LYG. The main cost driver in the screening
strategy compared with non-screening was cost of elective
aortic repair (Table 4). Cost per QALY gained was 14 762 Euro
in base-case. The cost per QALY gained increased to 19 683
Euro in the scenario assuming a general reduction of quality
of life by 25% in thewhole population, and non-screeningwas
the dominant strategy when assuming a 10% reduction in
quality of life for patients with known un-repaired AAA.
The effect of the different parameters on ICER is pre-
sented in the sensitivity analysis in Table 5 and Fig. 2.
Table 1 Probabilities and costs used in the Markov model.
Parameter Probability or cost
in base-case
Tested range,
one-way sensitivity
analysis
References and comments
Age 73 years e Mean age in current report
Prevalence 3.1% 0.8e6.5 Current report; 22
Proportion of opportunistically
detected AAA
13% 5e20% 1, 3, 32, 33
Proportion qualified and fit for surgery directly
(within half a year from screening)
5.0% e Current report; 9 elective
repairs in 181 patients
during the first
six months after
detection of AAA.
AAAs yearly risk for elective AAA surgery,
screened group
3.1% 1.0e3.9% Current report; 30 elective
repairs performed in 172 remaining
patients during the 5.2 remaining
years of survival
follow-up; 1, 3, 32, 33
AAAs yearly
risk for elective AAA surgery,
non-screened group
1.4% 0.5e2.0% 1, 3, 32, 33
Perioperative mortality
for elective AAA surgery
3.2% 2.7e3.6 29
(Swedish vascular registry analysis)
Ruptured AAA total mortality 79% 71e84% 1, 3, 17
AAAs yearly
risk of rupture,
screened group
0.8% 0.4e1.7% Current report; 1, 3, 32, 33
AAAs yearly
risk of rupture,
non-screened group
1.9% 1.4e2.4% 1, 3, 32, 33
Proportion of rAAA operated on 50% 30e70% 1, 2
Standardised mortality
ratio among AAA patients
2.0 1.4e3.0 Current report, 28
Cost of screening 4 Euro 0e60 Current report, 17
Cost of follow-up,
per year
277 200e400 Current report
Cost of non-ruptured AAA surgery 22628 Euro 19580e25674 26
Cost of surgery
for ruptured AAA
1.5 cost
of elective repair
1.3e4 cost of
elective repair
34e36
Cost of follow-up after AAA surgery 4515 Euro e 26
Discounting 3% e Annual discount
AAAZ Abdominal aortic aneurysm.
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This long-term evaluation of a selective AAA screening
programme among approximately 6000 patients with sus-
pected arterial disease referred to a vascular laboratory
verifies that screening is cost-effective, despite a high
frequency of co-morbidities and low relative survival. The
fact that every Swedish citizen has a unique personal
identification number and the uniformity of the Swedish
health-care system with public hospitals as the only
providers of major vascular surgery made it possible to
obtain 100% follow-up.
There are important limitations to this study. The AAA
screening at the vascular laboratory was not all-embracing,
and aortic measurement was not performed in one-third of
the patients referred to the vascular laboratory. While therate of patients who underwent aortic screening increased
over time during the study period, the prevalence of AAAwas
constant.22 Referral patterns with different indications for
arterial duplex examination between hospitals affect the
generalisability of the results. The retrospective nature of
the study makes the healtheeconomic evaluation of the
selective screening strategy partly dependent on literature
data. However, the sensitivity analysis performed in the
healtheeconomic evaluation allowed us to assess the effect
of the uncertainties introduced by the above-mentioned
limitations. The sensitivity analysis of the healtheeconomic
model gives a comprehensive overview of the effect of each
individual parameter on the cost-effectiveness of screening.
However, the one-way sensitivity analysis is an artificial
simplification of the real-life scenario where all parameters
are inter-linked and a change in one parameter may result in
Table 2 Patients’ characteristics.
All Elective repair No elective repair P
N 181 39 (21.5%) 142 (78.5%)
Mean age, years 72.8 66.5 74.5 <0.001
Mean aneurysm diameter,a mm 37.7 44.1 35.9 <0.001
Male, % 77.9 82.1 76.8 0.663
Arterial stenosis on duplex scan, % 56.4 64.1 54.2 0.195
Referral indication, n all (n positive scans) 0.090
Carotid artery duplex 92 (36) 17 (7) 75 (29)
Extremity artery duplex 51 (42) 17 (14) 34 (28)
Renal artery duplex 36 (9) 5 (0) 31 (9)
Otherb 2 (2) 0 2 (2)
Comorbidities
Cardiac 64.8% 56.4 67.2 0.255
Pulmonary 15.9% 17.9 15.3 0.804
Renal 23.3% 15.4 25.5 0.206
Diabetes 13.6% 10.3 14.6 0.603
Cerebrovascular 54.5% 53.8 54.7 1.0
a Diameter at detection.
b Patients with several arterial examinations without clear notification of the original indication of the duplex scan (renal and
extremity artery in one case, renal, carotid and extremity artery in the other case).
212 K. Mani et al.changes in several other parameters. Due to the small
number of AAA patients in each group, no subgroup analysis
was performed to evaluate cost-effectiveness of screening
based on initial cause of referral.
The overall prevalence of AAA in the selective screening
setting was 3.1%.22 However, it is important to note that 45%
of thescreenedpopulationwas female, and themeanagewas
66.5 years. Patients with an AAA detected by screening in the
present setting had a high level of cardiovascular co-
morbidity (Table 2), affecting long-term survival and cause ofTable 3 Cause of death among patients with AAA detec-
ted at selective screening.
Cardiovascular
Cardiac 44.2%
Cerebrovascular 12.6%
Aortic disease 8.5%
AAA rupture 3.2%
AAA postoperative a 4.2%
Aortic dissection 1.1%
Other vascularb 2.1%
Total 67.4%
Other
Cancer 8.4%
COPD 5.3%
Other
non-vascularc
15.8%
Unknown 3.2%
Total 32.6%
AAA: Abdominal aortic aneurysm; COPD: Chronic obstructive
pulmonary disease.
a All deaths related to previous AAA repair; includes both
early and late postoperative complications.
b Ischemic visceral disease.
c Includes sepsis, trauma, diabetes, psychiatric, gastro-
intestinal, and renal disease.death as well as potential operability and follow-up routines.
Relative 5-year survival in this patient cohort (80%) was lower
than for patients undergoing AAA repair in Sweden as a whole
(approximately 90%).28 The perioperative mortality of 5.1%
was higher than the reportedmortality for elective infrarenal
AAA repair in Sweden (3.2%).29 However, the perioperative
deaths occurred only in patients with pararenal and thoraco-
abdominal aortic aneurysms. A lower proportion of the
patients with a detected AAA were operated on electively in
this study (3.5% per year) compared with what has been
reported in previous randomised screening trials of the
general male population (5.1e6.5% per year),1,4 and a large
proportion were not followed up despite a small AAA having
beendetectedat screening.The fact that screeningmayhave
been performed in patients not regarded as suitable candi-
dates for follow-up, nor for surgery, is ethically questionable.
However, in the clinical setting, the riskebenefit analysis is
made on an individual basis. It is possible that some patients
who were not candidates for follow-up for a small AAAwould
have been regarded to benefit from repair if they had had
a large AAA at screening. Most patients not included in
a surveillance programme had small aneurysms, older age
and/or significant co-morbidities, explaining why follow-upTable 4 Base-case cost of screening for AAA among
patients referred for arterial duplex examination, per
person in Euro.
Cost Non-screening Screening Difference
Screening 0.0 4.0 4.0
Follow-up 19.5 48.4 28.9
Elective surgery 62.5 154.0 91.6
Ruptured surgery 63.6 25.1 38.5
Follow-up after
AAA repair
15.6 31.2 15.5
Total cost 161.2 262.7 101.5
Table 5 One-way sensitivity analysis of Markov model, per person in Euro.
Parameter Assumption Cost
differencea
Difference
in life years
Cost per life
year gained
Base case e 101.53 0.0092 11 084
AAA prevalence
Women without stenosis 0.8% 29.17 0.0024 12 339
Women with stenosis 2.7% 88.95 0.0080 11 148
Men without stenosis 2.9% 95.24 0.0086 11 114
Men with stenosis 6.5% 208.50 0.0192 10 855
Proportion of opportunistically detected AAA 5% 111.69 0.0092 12 193
20% 95.62 0.0092 10 438
AAAs yearly risk of non-ruptured repair,
screened group
1.0% 18.00 0.0093 1941
3.9% 129.04 0.0091 14 141
AAAs yearly risk for non-ruptured AAA surgery,
non-screened group
0.5% 140.47 0.0094 14 949
2.0% 77.42 0.0090 8594
Mortality for non-rupture AAA surgery 2.7% 101.62 0.0093 10 946
3.6% 101.46 0.0091 11 197
Ruptured AAA total mortality 71% 100.71 0.0082 12 353
84% 102.04 0.0098 10 423
AAAs yearly risk of rupture, screened group
0.4% 92.57 0.0124 7475
Registered ruptures, current report 0.6% 97.10 0.0108 9024
Assuming 10% miss-diagnosis of ruptures as
cardiac deaths in current report
1.3% 112.22 0.0053 21 305
1.7% 120.38 0.0023 53 341
AAAs yearly risk of rupture, non-screened group 1.4% 115.31 0.0051 22 798
2.4% 88.45 0.0131 6748
Proportion of rAAA operated 30% 116.92 0.0092 12764
70% 86.14 0.0092 9404
AAA patient relative long term mortality 1.4 108.88 0.0123 8867
3.0 92.29 0.0063 14 652
Cost of screening 0 97.53 0.0092 10 647
60 157.53 0.0092 17 197
Cost of follow-up, per year 200 93.49 0.0092 10 206
400 114.37 0.0092 12 485
Cost of non-ruptured AAA surgery 19 580 89.20 0.0092 9737
25 674 113.86 0.0092 12 429
Cost of surgery for ruptured AAA 1.3x elective 106.66 0.0092 11 644
4.0x elective 37.41 0.0092 4084
AAAZ Abdominal aortic aneurysm.
a Compared to non-screening.
Selective Screening for AAA 213was not indicated. If more patients had been subjected to
follow-up, the cost of screening and follow-up would have
increased. However, one registered fatal rupture in a patient
who was not followed-up could potentially have been avoi-
ded. Nevertheless, this raises the question whether there
should be specific inclusion and exclusion criteria for
screening high-risk individuals. This issue, however, would
have to be addressed in a prospective trial.
Despite the above-mentioned effects of co-morbidity on
survival, operability and follow-up, screening was cost-
effective. Screening for AAA among patients with athero-
sclerotic disease is often suggested based on the expected
high prevalence of disease. However, sensitivity analysis
showed that there is only a small healtheeconomic benefit
for screening with increasing prevalence of AAA above
a threshold level of w1% (Fig. 2A). Because AAA screeningwas a short additional examination of patients already
present at the vascular laboratory, the screening event took
little time and there was no associated cost of invitation,
travel or loss of income. The low cost of screening affected
the healtheeconomic evaluation positively. The high
mortality rate affected cost-effectiveness negatively, but
the ICER was well below the estimated willingness-to-pay
level of 50 000 Euro/LYG in all scenarios (Table 5 and Fig. 2B).
Less than one-third of the elective AAA repairs in this
study were performed with endovascular aneurysm repair
(EVAR). The increased use of EVAR might affect the cost-
effectiveness of a screening programme in several ways.
EVAR could increase the number of patients offered elec-
tive AAA repair in this selected cohort with high rate of
co-morbidities, thus reducing the number of ruptures. This,
together with the lower perioperative mortality associated
Figure 2 Incremental cost-effectiveness of selective screening based on A) varying prevalence of AAA and B) relative standardised
mortality rate compared to the general population adjusted for age, gender and calendar year (e.g. a relative standardised mortality
rate of two equals a twice as high mortality rate in the study population compared to the matched population). AAAZ Abdominal
aortic aneurysm; LYGZ Life years gained.
214 K. Mani et al.with EVAR, could result in a lower number of aneurysm-
related deaths in the screening population when more
patients are treated endovascularly, increasing the health
effect gained through screening. Conversely, increased
operative activity would also be associated with a higher
cost as more patients are operated on. It is possible that
the follow-up cost after EVAR would increase the total cost
of AAA repair in the long term.26 A higher cost and a better
outcome after EVAR may lead to a similar cost-effective-
ness ratio as in the current report.
The incremental cost-effectiveness of screening
compared with non-screening surpassed the threshold will-
ingness-to-pay level under two circumstances: (1) when
assuming a very high rupture rate in the screened population
(Table 5) and (2) when assuming a decreased utility inpatients with a known AAA (the latter resulting in lower total
QALY and higher cost). Despite the low elective operation
rate in the cohort, registered rupture rate among the selec-
tively screening detected AAAs in this study (0.6% per year)
was not higher than what has been reported for AAAs
detected in general male population screenings (0.6e1.2%
per year).1,4 However, the actual rupture rate in the cohort is
uncertain due to the low autopsy rate in Sweden. An
assumption that 10% of the cardiac deaths in the cohort were
mis-diagnosed AAA ruptures rendered an ICER of 21 305 Euro/
LYG for screening.
Owing to lack of actual data on utility among AAA
patients, data from the general Swedish population were
used.27 Considering the selected population in this study
with a high burden of cardiovascular disease, it is likely that
Selective Screening for AAA 215the utility level would be lower than a normal age-matched
heath utility index. Even when assuming a 25% lower utility
in the screening cohort compared with the general pop-
ulation in the sensitivity analysis, the ICER was below the
willingness-to-pay threshold. Although data on the effect of
a known AAA on the individual’s quality of life are scarce
and inconsistent,1,30 there are no strong data to assume
a consistent reduction in utility solely due to the knowledge
of having an AAA. Still, the drastic effect of a hypothetical
10% decrease in utility after AAA detection on the healthe
economic value of screening points out the importance of
this field for further studies.
In the current report, 50 000 Euro/LYG was used as
a threshold level for cost-effectiveness. In reality, there is
no explicit threshold level that is ubiquitously accepted.
Some argue that the public acceptance for use of resources
on health care is even higher than 50 000 Euro/LYG.25
However, the National Institute for Health and Clinical
Excellence in the United Kingdom uses a cost-effectiveness
threshold range of £20 000e30 000.31 However, a lowering
of the willingness-to-pay threshold to 25 000 Euro/LYG in
the current report would not change the conclusion, as the
sensitivity analysis showed that the ICER was below this
level for most scenarios.
The cost-effectiveness of the present selective high-risk
screening strategy was not as favourable as that described
for general screening of the elderly male population.5,17
According to the Multicentre Aneurysm Screening Study
(MASS) trial, the cost/LYG of screening elderly men was
9880 Euro after a 10-year follow-up, and was expected to
decrease to 2990 Euro over the full lifetime for men aged
65.5 General screening of men aged 65e75 years is being
implemented in several countries.6,7 This would probably
decrease the prevalence of previously unknown AAA in the
population of selectively screened patients at the vascular
laboratory. However, general screening of men 65 years
would not affect the detection rate of AAAs in male
patients below 65 or female patients. The Markov model
analysis showed that screening was cost-effective despite
a low prevalence in these patient groups. Furthermore,
screening among patients at the vascular laboratory does
not add any administrative burden on the laboratory. Thus,
it seems reasonable to continue with screening in this
setting.
Conclusions
Patients with AAA detected in selective screening at the
vascular laboratory had a high level of morbidity and infe-
rior long-term survival when compared with the general
population. Elective AAA repair rate was lower in this group
than in patients with AAA detected in general screening
programmes, with an acceptable perioperative mortality
rate. Despite these factors, selective screening for AAA
among patients referred to the vascular laboratory for
suspected arterial disease was cost-effective under most
assumptions with an estimated ICER at base-case of 11 084
Euro/LYG compared with non-screening.
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